Table 2 Association of indices of insulin resistance and β-cell function to glucose tolerance status

Adipo-IR

 Q1 (≤ 1.52)

Ref.

Ref.

Ref.

Ref.

 Q2 (1.53–2.37)

2.35 (1.29–4.29)

2.78 (1.44–5.38)

0.68 (0.26–1.76)

0.71 (0.21–2.38)

 Q3 (2.38–3.70)

2.47 (1.36–4.49)

2.74 (1.37–5.46)

1.00 (0.41–2.44)

0.84 (0.26–2.78)

 Q4 (≥ 3.71)

6.40 (3.43–11.92)

7.03 (3.23–15.32)

1.53 (0.67–3.49)

1.74 (0.51–5.96)

HOMA-IR

 Q1 (≤ 0.87)

Ref.

Ref.

Ref.

Ref.

 Q2 (0.88–1.29)

1.46 (0.82–2.61)

1.31 (0.68–2.50)

0.54 (0.19–1.51)

0.32 (0.09–1.09)

 Q3 (1.30–1.91)

2.00 (1.13–3.54)

1.77 (0.87–3.60)

1.30 (0.55–3.07)

0.85 (0.28–2.61)

 Q4 (≥ 1.92)

3.76 (2.06–6.84)

3.01 (1.40–6.48)

2.19 (0.98–4.91)

0.74 (0.22–2.46)

HOMA-β

 Q1 (≤ 40.12)

Ref.

Ref.

Ref.

Ref.

 Q2 (40.13–56.04)

0.71 (0.40–1.27)

0.62 (0.33–1.19)

0.43 (0.21–0.90)

0.45 (0.17–1.22)

 Q3 (56.05–80.23)

1.07 (0.61–1.87)

0.90 (0.46–1.76)

0.19 (0.08–0.42)

0.11 (0.04–0.34)

 Q4 (≥ 80.24)

1.31 (0.74–2.30)

0.87 (0.41–1.86)

0.27 (0.13–0.56)

0.22 (0.08–0.66)

Fasting CPRI

 Q1 (≤ 1.16)

Ref.

Ref.

Ref.

Ref.

 Q2 (1.17–1.48)

0.97 (0.54–1.76)

0.73 (0.39–1.38)

0.84 (0.40–1.74)

1.00 (0.38–2.64)

 Q3 (1.49–1.92)

1.81 (1.02–3.19)

1.25 (0.65–2.41)

0.31 (0.14–0.69)

0.24 (0.07–0.75)

 Q4 (≥ 1.93)

2.20 (1.24–3.91)

1.27 (0.61–2.66)

0.38 (0.18–0.80)

0.26 (0.08–0.83)

Postprandial CPRI

 Q1 (≤ 4.41)

Ref.

Ref.

Ref.

Ref.

 Q2 (4.42–5.53)

1.35 (0.76–2.41)

1.14 (0.60–2.13)

0.18 (0.08–0.41)

0.16 (0.06–0.46)

 Q3 (5.54–7.08)

1.11 (0.62–1.99)

0.78 (0.41–1.48)

0.14 (0.05–0.35)

0.22 (0.08–0.63)

 Q4 (≥ 7.09)

0.85 (0.47–1.53)

0.55 (0.28–1.07)

0.07 (0.02–0.24)

0.08 (0.02–0.31)